

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Submission Type | Name of Trial | Date of Receipt of Valid Research Application (old metric) | Date Site Invited (new metric) | Date Site Selected (new metric) | HRA Approval Date (new metric) | Date Site Confirmed By Sponsor (new metric) | Date Site Confirmed (new metric) | Date Site Ready to Start (new metric) | Date of First Patient Recruited | Non-Confirmation Status (new metric) | Duration between VRA / Date site selected and First Patient (days) | Benchmark Met | A - Permissions delayed/ denied | B - Suspended by sponsor | C - Closed by sponsor | D - Sponsor Delays | E - Staff availability issues | F - No patients seen | G - No patients consented | H - Contracting delays | I - Rare diseases | J - Other | Comments | Reasons for delay correspond to: | | |
|--|--|-----------------|--|--|--------------------------------|---------------------------------|--------------------------------|---|----------------------------------|---------------------------------------|---------------------------------|--------------------------------------|--|---------------|---------------------------------|--------------------------|-----------------------|--------------------|-------------------------------|----------------------|---------------------------|------------------------|-------------------|-----------|----------|--|--|--------------|
| 13/NS/0155 | 139913 | NHS Permission | A multicentre randomised controlled trial comparing laparoscopic supracervical hysterectomy with second generation endometrial ablation for the treatment of heavy menstrual bleeding (HEALTH) | 04/11/2015 | | | | | | | 01/03/2016 | | 118 | No | | | | | | | | | | | | No eligible patients seen until first patient consented. | Neither | |
| 15/LO/1035 | 164893 | NHS Permission | Multinational Abluminal Sirolimus Coated BioEngineered Stent The MAScot Post Marketing Registry | 18/09/2015 | | | | | | | 30/10/2015 | | 42 | Yes | | | | | | | | | | | | | | |
| 15/SC/0448 | 183584 | NHS Permission | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. | 12/10/2015 | | | | | | | 09/12/2015 | | 58 | Yes | | | | | | | | | | | | | | |
| 15/SW/0194 | 185459 | NHS Permission | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease | 12/10/2015 | | | | | | | 06/01/2016 | | 86 | No | | | | | | | | | | | | | No response from potential participants from invitation letters. | Neither |
| 15/SC/0397 | 183591 | NHS Permission | An evaluation of the tolerance, and acceptability of an amino acid based feed for children | 16/12/2015 | | | | | | | 04/03/2016 | | 79 | No | | | | | | | | | | | | | Mixture of ineligible patients and patients not wishing to consent to study. | Neither |
| 13/NS/0103 | 101577 | NHS Permission | PREEMPT: Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy | 19/01/2016 | | | | | | | 25/05/2016 | | 127 | No | | | | Y | | Y | | | | | | | Site not activated by sponsor until 29/02/2016. Six patients have since been screened, one of whom consented but was subsequently found to be ineligible during the screening laparoscopy. | Neither |
| 14/SC/0171 | 120104 | NHS Permission | A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumours. | 26/01/2016 | | | | | | | 25/04/2016 | | 90 | No | Y | | | | | | | | | | | | Delay in approval by site team due to capacity issues surrounding HRA transition and general staff capacity. Site not activated by sponsor until 08/04/2016. | NHS Provider |
| 15/WA/0106 | 167739 | NHS Permission | Protective Ventilation with Higher versus Lower PEEP during General Anesthesia for Surgery in OBESE Patients ? The PROBESE Randomized Controlled Trial | 07/01/2016 | | | | | | | 01/03/2016 | | 54 | Yes | | | | | | | | | | | | | | |
| 15/SC/0461 | 180750 | NHS Permission | A pilot study to investigate whether the permeability of the intestinal mucosa is altered after Gastric Bypass surgery in patients with Type 2 diabetes. | 01/03/2016 | | | | | | | 14/03/2016 | | 13 | Yes | | | | | | | | | | | | | | |
| 11/LO/1261 | 74423 | NHS Permission | Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum | 19/01/2016 | | | | | | | 02/06/2016 | | 135 | No | Y | | | | Y | Y | | | | | | | Delay in approval by site team due to capacity issues surrounding HRA transition. Subsequently no eligible patients seen since approval; strict inclusion criteria. | NHS Provider |

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Submission Type | Name of Trial | Date of Receipt of Valid Research Application (old metric) | Date Site Invited (new metric) | Date Site Selected (new metric) | HRA Approval Date (new metric) | Date Site Confirmed By Sponsor (new metric) | Date Site Confirmed (new metric) | Date Site Ready to Start (new metric) | Date of First Patient Recruited | Non-Confirmation Status (new metric) | Duration between VRA / Date site selected and First Patient (days) | Benchmark Met | A - Permissions delayed/ denied | B - Suspended by sponsor | C - Closed by sponsor | D - Sponsor Delays | E - Staff availability issues | F - No patients seen | G - No patients consented | H - Contracting delays | I - Rare diseases | J - Other | Comments | Reasons for delay correspond to: | |
|--|--|-----------------|---|--|--------------------------------|---------------------------------|--------------------------------|---|----------------------------------|---------------------------------------|---------------------------------|--------------------------------------|--|---------------|---------------------------------|--------------------------|-----------------------|--------------------|-------------------------------|----------------------|---------------------------|------------------------|-------------------|-----------|---|---|---------|
| 15/EE/0010 | 138590 | NHS Permission | Phase III trial in Intrahepatic Cholestasis of Pregnancy (ICP) to Evaluate ursodeoxycholic acid (UDCA) in improving perinatal outcomes | 03/05/2016 | | | | | | | 10/06/2016 | | 38 | Yes | | | | | | | | | | | | | |
| 14/EE/1293 | 164389 | NHS Permission | The Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes (C-STICH) Trial: A Randomised Controlled Trial of monofilament versus braided sutures for insufficient cervix. | 03/06/2016 | | | | | | | | | | No | | | | | | Y | | | | | | This is an unusual condition and no eligible patients seen to date. | Neither |
| 15/SC/0257 | 173423 | NHS Permission | Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis : a feasibility randomised controlled trial | 08/04/2016 | | | | | | | 26/08/2016 | | 140 | No | | | | | | Y | | | Y | | The sponsor requested the SSI form be validated prior to all study documentation being ready due to HRA transition.Small number of patients required with tight inclusion criteria for this palliative care research project. | Neither | |
| 15/NW/0551 | 183489 | NHS Permission | Improving teenage self-management of asthma: Randomised Controlled Trial | 04/03/2016 | | | | | | | 14/04/2016 | | 41 | Yes | | | | | | | | | | | | | |
| 16/EM/0133 | 184873 | HRA Approval | A randomised, double-blind, placebo-controlled multicentre study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis | | 09/06/2016 | 09/06/2016 | 19/04/2016 | 29/09/2016 | 07/10/2016 | | | N/A | | No | | | | | | | | Y | | Y | SIV 13/09/16. Radiology capacity issues. Contract delayed by sponsor. | Both | |
| 16/WS/0068 | 199202 | HRA Approval | Quantitative Fibronectin to help Decision-making in women with Symptoms of Preterm Labour - QUIDS | | 19/05/2016 | 10/08/2016 | 13/07/2016 | 27/06/2016 | 10/08/2016 | | | N/A | | No | | | Y | Y | | | | | | | Amended study documentation presented by sponsor at SIV which necessitated additional communication to resolve agreement to continue. | Both | |
| 16/EM/0193 | 190690 | HRA Approval | A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial | | 09/03/2016 | 03/06/2016 | 14/06/2016 | 04/10/2016 | 10/10/2016 | | | N/A | | No | | | Y | | | | | | | | SIV planned 17/10/16. Sponsor and HRA delays regarding requirement for a material transfer agreement - created significant delays. | Sponsor | |